tesmilifene + epirubicin + cyclophosphamide

Tesmilifene + epirubicin + cyclophosphamide is an investigational **three-drug combination chemotherapy regimen** primarily evaluated for the treatment of metastatic breast cancer. Tesmilifene is a non-steroidal antiestrogen compound studied for its chemosensitizing properties. Epirubicin is an anthracycline chemotherapeutic agent that inhibits DNA and RNA synthesis through topoisomerase II inhibition. Cyclophosphamide is an alkylating agent that cross-links DNA strands, leading to apoptosis in rapidly dividing cancer cells. The combination is intended to enhance antitumor effects with distinct, but complementary, mechanisms: tesmilifene may increase the efficacy of cytotoxic chemotherapy through potential modulation of drug resistance, epirubicin blocks cellular replication via DNA damage, and cyclophosphamide induces cell death by DNA alkylation[2].

Other names

tesmilifeneepirubicincyclophosphamide